Topic

Pennsylvania

A collection of 524 issues

Myths vs. Facts: Getting Tecentriq (atezolizumab) Covered by Aetna (CVS Health) in Pennsylvania

Answer Box: Tecentriq (atezolizumab) requires prior authorization from Aetna (CVS Health) in Pennsylvania, with approval based on FDA-indicated use, PD-L1 testing results (≥1% for adjuvant NSCLC, ≥50% for first-line metastatic), and documentation of failed alternatives where required. If denied after internal appeal, Pennsylvania's Independent External Review program offers

How to Get Cerezyme (Imiglucerase) Covered by Humana in Pennsylvania: Complete Coverage Guide

Answer Box: Your Path to Coverage Humana classifies Cerezyme (imiglucerase) as a nonpreferred drug requiring prior authorization and step therapy to preferred agents (Elelyso or Vpriv) first. To get coverage in Pennsylvania: (1) Submit PA request with Type 1 Gaucher disease diagnosis and step therapy documentation, (2) If denied, file

How to Get Upstaza (Eladocagene Exuparvovec) Covered by Cigna in Pennsylvania: Complete Forms, Appeals, and Contact Guide

Answer Box: Getting Upstaza Covered by Cigna in Pennsylvania Cigna requires prior authorization for Upstaza (eladocagene exuparvovec) through Express Scripts/Accredo, with specific criteria including genetic confirmation of AADC deficiency and failed standard therapies. Submit via CoverMyMeds portal or call 800-753-2851 with genetic testing, severity assessment, and certified neurosurgical center

Renewing Prolastin-C Coverage with Cigna in Pennsylvania: Complete 2025 Guide to Authorization, Appeals, and Timing

Answer Box: Fastest Path to Prolastin-C Renewal Cigna requires annual reauthorization for Prolastin-C in Pennsylvania. Start your renewal 60-90 days before expiration by gathering updated spirometry (within 6 months), recent clinical notes from your pulmonologist, and documentation of continued clinical benefit. Submit via your provider's Cigna portal or

How to Get Onivyde (Irinotecan Liposome) Covered by Blue Cross Blue Shield in Pennsylvania: Complete Appeal Guide with Forms and Timelines

Quick Answer: Getting Onivyde Covered by Blue Cross Blue Shield in Pennsylvania Blue Cross Blue Shield plans in Pennsylvania require prior authorization for Onivyde (irinotecan liposome) as a specialty cancer treatment. Submit PA requests through your plan's provider portal with pathology-confirmed metastatic pancreatic adenocarcinoma, ECOG performance status 0-1,

How to Get Vitrakvi (larotrectinib) Covered by Blue Cross Blue Shield in Pennsylvania: PA Forms, Appeals, and Success Strategies

Answer Box: Getting Vitrakvi Covered by Blue Cross Blue Shield in Pennsylvania Vitrakvi (larotrectinib) requires prior authorization from Blue Cross Blue Shield plans in Pennsylvania for NTRK fusion-positive solid tumors. The fastest path to approval: (1) Submit PA with confirmed NTRK fusion testing results and documentation of metastatic/unresectable disease,

How to Get Opzelura (Ruxolitinib Cream) Covered by Humana in Pennsylvania: Prior Authorization Guide and Appeal Process

Answer Box: Your Path to Opzelura Coverage Opzelura (ruxolitinib cream) requires prior authorization from Humana Medicare Advantage plans in Pennsylvania. Your dermatologist must document failed trials of at least two topical treatments (like corticosteroids and calcineurin inhibitors) for atopic dermatitis, or failed conventional therapies for vitiligo. Submit requests through Humana&

How to Get Enhertu (fam-trastuzumab deruxtecan-nxki) Covered by Cigna in Pennsylvania: Complete Appeals Guide with Forms & Timelines

Answer Box: Getting Enhertu Covered by Cigna in Pennsylvania Fastest path to approval: Submit prior authorization through Cigna's provider portal with documented HER2-positive status, prior therapy failures, and NCCN guideline support. If denied, request peer-to-peer review within 7-14 days, then file internal appeals within 180 days. Pennsylvania residents

Myths vs. Facts: Getting Filsuvez (birch triterpenes topical gel) Covered by UnitedHealthcare in Pennsylvania

Answer Box: Getting Filsuvez (birch triterpenes topical gel) covered by UnitedHealthcare in Pennsylvania requires prior authorization with genetic confirmation of dystrophic or junctional epidermolysis bullosa, wound documentation, and age ≥6 months. First step: enroll in Chiesi Total Care for PA support. If denied, Pennsylvania's external review program overturns

A Realistic Alecensa (Alectinib) Approval Scenario with Cigna in Pennsylvania (From Request to Yes)

Answer Box: Getting Alecensa (Alectinib) Approved by Cigna in Pennsylvania Quick Path to Approval: Cigna requires prior authorization for Alecensa (alectinib) in ALK-positive NSCLC. Submit documented ALK-positive test results, pathology confirming NSCLC, and prescriber attestation via Cigna's PA portal. Most approvals occur within 72 hours for metastatic cases;